Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28969335 | 0.79 | MEN1 (0.46) | MEN1KMT2ACYP3A4CYP2C9POLB | |
| SCHEMBL8385965 | 0.79 | MEN1 (0.44) | MEN1KMT2ACYP3A4CYP2C9POLB | |
| SCHEMBL6970534 | 0.78 | POLB (0.43) | MEN1KMT2ACYP3A4CYP2C9POLB | |
| SCHEMBL14800866 | 0.78 | MEN1 (0.43) | MEN1KMT2ACYP3A4CYP2C9POLB | |
| SCHEMBL18366033 | 0.78 | POLB (0.43) | MEN1KMT2ACYP3A4CYP2C9POLB | |
| SCHEMBL23066567 | 0.78 | PKM (0.43) | MEN1KMT2ACYP3A4CYP2C9POLB | |
| SCHEMBL2521727 | 0.78 | MEN1 (0.48) | MEN1KMT2ACYP3A4CYP2C9POLB | |
| SCHEMBL16523977 | 0.76 | POLB (0.42) | MEN1KMT2ACYP3A4CYP2C9POLB | |
| SCHEMBL15171010 | 0.76 | POLB (0.47) | MEN1KMT2APOLBL3MBTL1GAA | |
| SCHEMBL15567232 | 0.75 | L3MBTL1 (0.51) | MEN1KMT2ACYP3A4CYP2C9POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111484482-B | Alkynyl pyrimidine or alkynyl pyridine compound, and composition and application thereof | 北京赛特明强医药科技有限公司 | 2022-06-21 | — | — | CN | disclosed |
| EP-3312164-B1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES LLC (US) | 2020-12-09 | — | — | EP | disclosed |
| CN-111484482-A | Alkynyl pyrimidine or alkynyl pyridine compound, and composition and application thereof | 北京赛特明强医药科技有限公司 | 2020-08-04 | — | — | CN | disclosed |
| EP-3036231-B1 | SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | JUBILANT BIOSYS LTD (IN) | 2020-02-26 | — | — | EP | disclosed |
| US-10273224-B2 | Substituted pyrimidine compounds, compositions and medicinal applications thereof | JUBILANT BIOSYS LIMITED (IN) | 2019-04-30 | — | — | US | disclosed |
| EP-3312164-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | Calitor Sciences, LLC (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-3122729-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | Calitor Sciences, LLC (US) | 2017-02-01 | — | — | EP | disclosed |
| US-9403801-B2 | Substituted heteroaryl compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160207905-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | BLUEPRINT MEDICINES CORPORATION | 2016-07-21 | — | — | US | disclosed |
| US-20160207905-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | BLUEPRINT MEDICINES CORPORATION | 2016-07-21 | — | — | US | disclosed |
| US-20160207905-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | BLUEPRINT MEDICINES CORPORATION | 2016-07-21 | — | — | US | disclosed |
| EP-3036231-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | Jubilant Biosys Ltd. (IN) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015148867-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-10-01 | — | — | WO | disclosed |
| US-20150274704-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-10-01 | — | — | US | disclosed |
| CN-104926795-A | Substituted heteroaryl compound, and composition and application thereof | GUANGDONG HEC PHARMACEUTICAL | 2015-09-23 | — | — | CN | disclosed |
| WO-2015025197-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | JUBILANT BIOSYS LIMITED (IN) | 2015-02-26 | — | — | WO | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207905-A1 | SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | TYMP, EGFR, TK1 | MEN1 4787/4885KMT2A 4738/4885CYP3A4 1938/4885 |
| US-20150274704-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | PRKACA, PRKDC, PRKACB | MEN1 2419/4885KMT2A 1385/4885CYP3A4 2409/4885 |
| US-10273224-B2 | Substituted pyrimidine compounds, compositions and medicinal applications thereof | TYMP, EGFR, TK1 | MEN1 4787/4885KMT2A 4738/4885CYP3A4 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.